| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
|
N Engl J Med
|
2008
|
6.32
|
|
2
|
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
|
Lancet
|
2007
|
5.41
|
|
3
|
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
|
Arch Cardiovasc Dis
|
2013
|
2.71
|
|
4
|
Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study.
|
Thromb Res
|
2012
|
1.58
|
|
5
|
The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study.
|
Anesth Analg
|
2007
|
1.55
|
|
6
|
Postoperative myocardial damages after hip fracture repair are frequent and associated with a poor cardiac outcome: a three-hospital study.
|
Age Ageing
|
2009
|
1.48
|
|
7
|
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.
|
Haematologica
|
2003
|
1.00
|
|
8
|
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
|
Int Orthop
|
2011
|
0.98
|
|
9
|
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
|
Thromb Res
|
2012
|
0.98
|
|
10
|
Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim.
|
Crit Rev Oncol Hematol
|
2010
|
0.94
|
|
11
|
The ''critical thrombosis period'' in major orthopedic surgery: when to start and when to stop prophylaxis.
|
Clin Appl Thromb Hemost
|
2009
|
0.94
|
|
12
|
An electronic tool for venous thromboembolism prevention in medical and surgical patients.
|
Haematologica
|
2006
|
0.94
|
|
13
|
Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.
|
Arch Intern Med
|
2002
|
0.90
|
|
14
|
Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study.
|
Anesth Analg
|
2002
|
0.87
|
|
15
|
Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments.
|
Crit Rev Oncol Hematol
|
2011
|
0.86
|
|
16
|
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
|
Thromb Haemost
|
2003
|
0.85
|
|
17
|
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.
|
Arch Cardiovasc Dis
|
2011
|
0.84
|
|
18
|
Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery.
|
Eur J Clin Pharmacol
|
2012
|
0.81
|
|
19
|
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
|
Pathophysiol Haemost Thromb
|
2006
|
0.81
|
|
20
|
How can we explain the gap between randomised studies and 'real life' practice in postoperative transfusion triggers? Do we need to change recommended thresholds for transfusion?
|
Eur J Anaesthesiol
|
2012
|
0.80
|
|
21
|
Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.
|
Thromb Haemost
|
2012
|
0.79
|
|
22
|
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
|
Thromb Res
|
2012
|
0.79
|
|
23
|
Tranexamic acid for trauma.
|
Lancet
|
2010
|
0.77
|
|
24
|
Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin.
|
Thromb Haemost
|
2004
|
0.77
|
|
25
|
Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery : Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety.
|
Clin Drug Investig
|
2005
|
0.76
|
|
26
|
Early administration of tranexamic acid in trauma patients.
|
Lancet
|
2011
|
0.75
|
|
27
|
Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
|
Thromb Haemost
|
2010
|
0.75
|
|
28
|
Prevention of postoperative venous thromboembolism. Risk assessment and methods of prophylaxis.
|
Can J Anaesth
|
2006
|
0.75
|
|
29
|
[Thromboprophylaxis in surgical patients].
|
Presse Med
|
2013
|
0.75
|
|
30
|
Neither pre-operative education or a minimally invasive procedure have any influence on the recovery time after total hip replacement.
|
Int Orthop
|
2015
|
0.75
|